BioPharmSignal logoBioPharmSignal

Biotech News

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

Insmed (INSM)InsmedClinical readout

INSM (INSM) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is insm.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

INSMInsmed2026-07-16 11:00 EST

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

INSMInsmed2026-05-04 11:00 EST

Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026

TBPHTheravance Biopharma2025-11-20 16:00 EST

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

VERUVeru Inc2026-07-27 12:10 EST

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

XAIRBeyond Air2026-04-20 12:00 EST

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

TBPHTheravance Biopharma2025-10-29 10:00 EST

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

VERUVeru Inc2026-05-13 10:30 EST

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

XAIRBeyond Air2026-03-17 20:35 EST

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

RVPHReviva Pharmaceuticals2026-01-08 13:00 EST

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

RVPHReviva Pharmaceuticals2025-10-28 12:00 EST

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

View all latest news

Insmed

Serious and Rare Diseases Insmed develops and commercializes therapies for serious pulmonary and rare diseases. Its portfolio combines marketed respiratory medicines with late-stage inhaled therapies and earlier gene-therapy programs. Commercial Respiratory Portfolio BRINSUPRI, or brensocatib, is a DPP1 inhibitor for non-cystic-fibrosis...

Recent company news

INSMInsmed2026-08-06 11:00 EST

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

INSMInsmed2026-07-23 11:00 EST

Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026

INSMInsmed2026-07-16 11:00 EST

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

INSMInsmed2026-06-23 11:00 EST

Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory

INSMInsmed2026-06-04 11:00 EST

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Stock data

Close
132.55 USD
Market cap
22.48B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States